Remove In-Vitro Remove Life Science Remove Pharma Companies
article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

To gain insight into the motivations, steps and experiences involved in an academia to industry — or vice versa — transition, Xtalks spoke to several leading scientists and entrepreneurs in pharma and biotech who successfully transitioned from academic positions to leadership roles in industry settings. A life-changing moment came for Dr.

article thumbnail

Touchlight boosts DNA manufacturing capacity with latest expansion

Pharmaceutical Technology

After raising $125m in 2021 to redevelop the facility, more recently Touchlight secured an additional $17.3m (£14m) from the UK government’s Life Sciences Innovative Manufacturing Fund to accelerate its expansion plans and scale-up equipment. Free Report How is the Biopharmaceutical industry evolving?

DNA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ABPI chief exec on the UK industry’s learnings from COVID-19

pharmaphorum

We’ve got so many great life science assets in the UK, but there are still some gaps – manufacturing capacity being one of them.”. “We We had companies collaborating to develop laboratories. We had companies sourcing consumables for testing machines. Strength in the second wave. We’re very grateful for that.

article thumbnail

Top 10 Biotech Trends for 2025

XTalks

In recent years, CRISPR has also been effectively applied to reduce or eliminate persistent viral infections in vitro and in animal models, raising hope for its use in treating latent and chronic viral infections. Related: Biotech IPOs in 2024: Navigating the New Wave of Innovation 1.